Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide
Authors
Samson, S. L.Nachtigall, L. B.
Fleseriu, M.
Gordon, M. B.
Bolanowski, M.
Labadzhyan, A.
Ur, E.
Molitch, M.
Ludlam, W. H.
Patou, G.
Haviv, A.
Biermasz, N.
Giustina, A.
Trainer, Peter J
Strasburger, C. J.
Kennedy, L.
Melmed, S.
Affiliation
Pituitary Center, Baylor St. Luke's Medical Center, Baylor College of Medicine, Houston, Texas, USA.Issue Date
2020
Metadata
Show full item recordAbstract
Purpose: The phase 3 CHIASMA OPTIMAL trial (NCT03252353) evaluated efficacy and safety of oral octreotide capsules (OOCs) in patients with acromegaly who previously demonstrated biochemical control while receiving injectable somatostatin receptor ligands (SRLs). Methods: In this double-blind study, patients (N = 56) stratified by prior SRL dose were randomly assigned 1:1 to OOC or placebo for 36 weeks. The primary end point was maintenance of biochemical control at the end of treatment (mean insulin-like growth factor 1 [IGF-1] ≤ 1.0 × upper limit of normal [ULN]; weeks 34 and 36). Time to loss of IGF-1 response and proportion requiring reversion to injectable SRLs were assessed as broader control measures. Results: Mean IGF-1 measurements were 0.80 and 0.97 × ULN for OOC and 0.84 and 1.69 × ULN for placebo, at baseline and end of treatment, respectively. Mean growth hormone (GH) changed from 0.66 to 0.60 ng/mL for OOCs and 0.90 to 2.57 ng/mL for placebo. Normalization of IGF-1 levels (≤ 1.0 × ULN) was maintained in 58.2% for OOCs vs 19.4% for placebo (P = .008); GH levels were maintained (< 2.5 ng/mL) in 77.7% for OOC vs 30.4% for placebo (P = .0007). Median time to loss of response (IGF-1 > 1.0 or ≥ 1.3 × ULN definitions) for patients receiving placebo was 16 weeks; for patients receiving OOCs, it was not reached for both definitions during the 36-week trial (P < .0001). Of the patients in the OOC group, 75% completed the trial on oral therapy. The OOC safety profile was consistent with previous SRL experience. Conclusions: OOCs may be an effective therapy for patients with acromegaly who previously were treated with injectable SRLs.Citation
Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, et al. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab. 2020;105(10).Journal
Journal of Clinical Endocrinology & MetabolismDOI
10.1210/clinem/dgaa526PubMed ID
32882036Additional Links
https://dx.doi.org/10.1210/clinem/dgaa526Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1210/clinem/dgaa526